INB-16

INmune Bio has partnered with Cell and Gene Therapy Catapult to establish commercial-scale manufacturing for CORDStrom, a promising therapy for recessive dystrophic epidermolysis bullosa that showed positive results in Phase 2 trials.

INmune Bio's Natural Killer cell therapy INKmune™ demonstrates strong safety profile in Phase I trial for metastatic castration-resistant prostate cancer, enabling progression to Phase II high-dose cohort.

INmune Bio announces plans to submit Biologics License Application (BLA) to FDA for CORDStrom following successful Type C meeting.

INmune Bio's CaRe PC trial, evaluating INKmune in metastatic castration-resistant prostate cancer (mCRPC), has expanded to the West Los Angeles VA Medical Center.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.